Arcus Biosciences stock drops 4.67% as Arcus Biosciences unveils BMS kidney cancer trial partnership

Arcus Biosciences stock drops 4.67% as Arcus Biosciences unveils BMS kidney cancer trial partnership
Arcus Biosciences falls 4.67% today

Arcus Biosciences announced a clinical trial collaboration and supply agreement with BMS to evaluate casdatifan in advanced kidney cancer.

Highlights

  • RCUS remains in a consolidative phase, facing near-term seller pressure but supported by sustained medium- and long-term bullish momentum.
  • Key support is at $23.75, with immediate resistance at $24.66; surpassing resistance could prompt a move toward $25.25.
  • Momentum indicators are mixed with weak trend conviction and localized overbought signals, while the weekly technicals favor ongoing upside with over 80% probability.

The agreement will test Arcus Biosciences' investigational HIF-2a inhibitor casdatifan in combination with a PD-L1/VEGF-A bispecific immunomodulator. The combination will be studied in the Phase 1/2 ROSETTA RCC-208 trial.

Short-term pressure as price stalls below key moving averages

RCUS is currently trading at $24.47, slightly below the MA-20 ($24.55) but above the MA-50 ($23.75) and well above the MA-200 ($20.16). This setup indicates near-term pressure from sellers, while the medium- and long-term structure remains bullish with strong upward support from the longer moving averages. The Ichimoku Kijun sits at $24.66, acting as immediate resistance for the price. Near-term support is seen at MA-50 ($23.75), with key support at MA-100 ($22.68). Immediate resistance is the Kijun ($24.66), while MA-20 ($24.55) serves as near-term resistance and MA-200 ($20.16) as key longer-term support.

Mixed momentum as buyers lose ground amid heightened volatility

Momentum on D1 is mixed, with a buy signal from MACD but a low ADX (10.19) indicating a weak trend. RSI is balanced at 50.78, while Stoch RSI signals strong sell conditions, and CCI remains neutral. BBP flags an overbought environment, highlighting short-term buyer dominance, but there is divergence among oscillators. The Awesome Oscillator supports the current bullish undertone. In today's session, RCUS is down 4.67% following a $1.20 loss against the previous close, signaling increased near-term volatility. Over the past week, the stock has declined $0.87 (3.43%) from $25.34, currently trading in the lower part of the weekly range. Weekly volatility stands at 11.37%. The persistent retreat from the weekly high suggests a steady decline with heightened pressure from sellers.

Bullish outlook dominates as consolidation holds above support

Looking ahead, the expected price corridor for the next week is $24.20 to $25.25, keeping the range tight and realistic based on current volatility and recent levels. On the W1 timeframe, all trend indicators (MA-50, RSI, ADX, MACD) point to sustained bullishness, setting the probability of an upside move at more than 80% and making a decline less likely. The baseline scenario expects RCUS to consolidate between $24.20 and $25.25 as it digests recent volatility. If bulls push through immediate resistance at $24.66, a move toward the upper end of the range is plausible. Conversely, failure to hold support at $23.75 could trigger a test of the lower band. This weekly range keeps RCUS well above its 52-week low of $7.91 and just below the yearly peak of $28.72, reflecting continued outperformance on a longer-term basis.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.